BNGO stock closed Tuesday trading at $2.0400 at close: 04:00 PM EDT
On October 4, Bionano Genomics (NASDAQ:BNGO) reported that a study found that whole genome sequencing (WGS) only identified 63% of structural alterations discovered by optical genome mapping (OGM) in liver cancer.
The research, conducted by a team from Sorbonne University and published in the journal Cancer Research, demonstrated the use of OGM to examine complex structural variations (SVs) brought on by replication stress in a molecular subgroup of hepatocellular carcinoma (HCC), the company stated in a press release on October 4.
According to Bionano (NASDAQ:BNGO), the study employed an OGM and WGS process to analyze complicated rearrangements and resolve them at base pair resolution, as well as to maximize the discovery of pathogenic and potentially pathogenic variants.
Imagine Your ROI If You Invested $1,000 In Bionano (Bngo) Stock At Its COVID-19 Pandemic Low.
Researchers were able to compare OGM and WGS utilizing the methodology, and they found that just 63% of SVs identified by OGM were also identified by WGS, according to the business.
According to the business, OGM showed a median of 1.4 times more SVs than WGS.
According to Erik Holmlin, president and chief executive officer of Bionano, “It demonstrates that OGM can be more sensitive for detecting big structural differences than WGS, and it provides a wonderful example of how compatible the two approaches are.”
The optical genome mapping (OGM) data services of Bionano Genomics (NASDAQ:BNGO) have been combined with the clinical testing services formerly provided by Lineagen to become Bionano Laboratories. According to a news release on September 23, the company also introduced the first OGM-based laboratory-designed test (LDT).
The business also mentioned that Bionano Laboratories’ lab in San Diego just gained CLIA certification.
BNGO stock outlook
The most recent quarterly earnings report from Bionano Genomics (NASDAQ:BNGO – Get Rating) was made public on Thursday, August 4. The company’s ($0.11) earnings per share (EPS) for the quarter fell short of the ($0.01) consensus estimate. Bionano Genomics reported a negative net margin of 453.68% and a negative return on equity of 33.21%. Analysts had predicted $6.20 million in sales for the company for the quarter; instead, it brought in $6.67 million. For the current fiscal year, on average, equity analysts forecast that Bionano Genomics will have -0.44 earnings per share.
Featured Image – Unsplash © nci
Author Jowi Kwasu 
